Patents by Inventor Morten Asser Karsdal

Morten Asser Karsdal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180238903
    Abstract: The invention provides an immunological binding partner specifically reactive with a C-terminal epitope of the ?1 chain of collagen Type VIII or with an N-terminal epitope of the mature form of the ?1 chain of collagen Type VIII, and a method of immunoassay for detecting or quantitating in a sample the C-terminal epitope or the N-terminal epitope of the mature ?1 chain of collagen type VIII.
    Type: Application
    Filed: August 16, 2016
    Publication date: August 23, 2018
    Applicant: Nordic Bioscience A/S
    Inventors: Niels Ulrik Brandt Hansen, Diana Julie Oernes-Leeming, Morten Asser Karsdal
  • Publication number: 20180105568
    Abstract: Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. A peptide selected from sequences SEQ ID NO: 12, SEQ ID NO: 15 and SEQ ID NO: 17 are administered.
    Type: Application
    Filed: December 4, 2017
    Publication date: April 19, 2018
    Applicant: KeyBioscience AG
    Inventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
  • Patent number: 9862754
    Abstract: Provided herein are peptides, that in combination with metformin, are effective for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. The peptides are selected from sequences SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.
    Type: Grant
    Filed: October 1, 2016
    Date of Patent: January 9, 2018
    Assignee: KeyBioscience AG
    Inventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
  • Publication number: 20170096467
    Abstract: Provided herein are peptides, that in combination with metformin, are effective for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. The peptides are selected from sequences SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.
    Type: Application
    Filed: October 1, 2016
    Publication date: April 6, 2017
    Applicant: KeyBioscience AG
    Inventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
  • Patent number: 9533022
    Abstract: Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. Treatment is effected with a combination therapy of metformin and a peptide with a sequence selected from SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24 administered to a patient.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: January 3, 2017
    Assignee: KeyBioscience A/S
    Inventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
  • Publication number: 20150196617
    Abstract: Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. Treatment is effected with a combination therapy of metformin and a peptide with a sequence selected from SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24 administered to a patient.
    Type: Application
    Filed: February 27, 2015
    Publication date: July 16, 2015
    Applicant: KEYBIOSCIENCE AG
    Inventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
  • Patent number: 9006172
    Abstract: A peptide having a sequence selected from SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18. Said peptide used for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of apetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: April 14, 2015
    Assignee: KeyBioscience AG
    Inventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen